Li Chen
Founder chez HUA MEDICINE (SHANGHAI) LTD.
Fortune : 679 533 $ au 31/03/2024
Profil
Li Chen is the founder of Hua Medicine Ltd., a company founded in 2009, where he currently holds the position of President, CEO & Executive Director.
He is also the founder of Hua Medicine (Shanghai) Co., Ltd., established in 2011, where he serves as Chairman, CEO & General Manager.
In addition to his founding roles, Dr. Chen currently holds positions as an Independent Director at Coland Holdings Ltd.
since 2014 and as a Director at Hua Medicine Technology (Hong Kong) Ltd.
since 2010.
He is also a Member at Roche Pharmaceuticals, Inc. and an Adjunct Professor at Tongji University.
Previously, Dr. Chen served as an Independent Director at Coland Pharmaceutical Co., Ltd.
from 2014 to 2020.
He was also the President & Director of the Sino-American Pharmaceutical Professionals Association, Chief Scientific Officer & Director at Roche R & D Center China Co. Ltd., and Principal at Hoffmann-La Roche, Inc. Furthermore, Dr. Chen worked as a Lecturer-Organic Chemistry at East China Normal University and as the Chief Scientific Officer & Head-Research at Roche (China) Co. Ltd.
Dr. Chen obtained a doctorate degree from Iowa State University in 1992 and undergraduate degrees from Zhengzhou University in 1982 and East China Normal University in 1985.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HUA MEDICINE LTD.
0,34% | 31/03/2023 | 3 618 000 ( 0,34% ) | 679 533 $ | 31/03/2024 |
Postes actifs de Li Chen
| Sociétés | Poste | Début |
|---|---|---|
| HUA MEDICINE (SHANGHAI) LTD. | Founder | 10/11/2009 |
| COLAND HOLDINGS LIMITED | Director/Board Member | 30/06/2014 |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
| Tongji University | Corporate Officer/Principal | - |
| Hua Medicine Technology (Hong Kong) Ltd. | Director/Board Member | 01/08/2010 |
Hua Medicine (Shanghai) Co., Ltd.
 Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Chief Executive Officer | - |
Anciens postes connus de Li Chen
| Sociétés | Poste | Fin |
|---|---|---|
Coland Pharmaceutical Co., Ltd.
 Coland Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Coland Pharmaceutical is a specialty pharmaceutical company focusing on marketing branded products and developing solid pipelines through collaboration with leading institutes. Its main interests are in the dedicated therapeutic areas Hepatitis, Immunology, Oncology, and other niche areas. Coland was started its sales operation in 2005. Daiding (Adefovir), a first-to-market generic that treats HBV was launched in 2005. With effective promotion, and brand building, Daiding achieved great success and gained the leading position in China. Its goal is to become a leading specialty pharmaceutical company in China with strong sales and marketing capabilities and solid product pipelines. The company was founded in 2003 and is headquartered in Shanghai, China. | Director/Board Member | 01/10/2020 |
| Roche R & D Center China Co. Ltd. | Chief Tech/Sci/R&D Officer | - |
| Sino-American Pharmaceutical Professionals Association | President | - |
| ░░░░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░░ ░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
Formation de Li Chen
| Iowa State University | Doctorate Degree |
| Zhengzhou University | Undergraduate Degree |
| East China Normal University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| HUA MEDICINE (SHANGHAI) LTD. | Health Technology |
| Entreprise privées | 9 |
|---|---|
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
| Roche (China) Co. Ltd. | |
Coland Pharmaceutical Co., Ltd.
Coland Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Coland Pharmaceutical is a specialty pharmaceutical company focusing on marketing branded products and developing solid pipelines through collaboration with leading institutes. Its main interests are in the dedicated therapeutic areas Hepatitis, Immunology, Oncology, and other niche areas. Coland was started its sales operation in 2005. Daiding (Adefovir), a first-to-market generic that treats HBV was launched in 2005. With effective promotion, and brand building, Daiding achieved great success and gained the leading position in China. Its goal is to become a leading specialty pharmaceutical company in China with strong sales and marketing capabilities and solid product pipelines. The company was founded in 2003 and is headquartered in Shanghai, China. | Health Technology |
Coland Holdings Ltd.
 Coland Holdings Ltd. Pharmaceuticals: MajorHealth Technology Coland Holdings Ltd. engages in the research, development, and sale of generic and traditional Chinese medicine, biochemical drugs, and medical equipment. It focuses on the treatment of hepatobiliary, respiratory system, tumor, and cardiovascular problems. The company was founded on March 23, 2010 and is headquartered in Shanghai, China. | Health Technology |
| Sino-American Pharmaceutical Professionals Association | |
| Hua Medicine Technology (Hong Kong) Ltd. | |
Hua Medicine (Shanghai) Co., Ltd.
Hua Medicine (Shanghai) Co., Ltd. BiotechnologyHealth Technology Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then. | Health Technology |
| Roche R & D Center China Co. Ltd. |
